COH
data caveat$6.5BCF+
Cochlear Limited
Hearing implants
World leader in implantable hearing devices (cochlear implants, bone-anchored hearing aids)
Data HealthTrials20 of 25 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$6.5B
Burn Rate
—
Dec 2025 4C
Shares Outstanding
65M
Pipeline Assets
4
Latest Insight(1)
22 Apr 2026substantial_holderChange in substantial holding
Changed·State Street Corporation and subsidiaries·9.33%
3M Price
COH.ASX$99.580-63.5% 3M
Low $99.580High $273.803
Pipeline Assets (4)
Nucleus 8 Sound ProcessorSevere to profound sensorineural hearing loss
ApprovedOsia 2 SystemConductive/mixed hearing loss (bone conduction)
ApprovedBaha 6 MaxSingle-sided deafness / conductive hearing loss
ApprovedCochlear Implant (CI600 series)Bilateral severe hearing loss
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Substantial Holders (5%+ threshold)
6 noticesarrow_drop_upState Street Corporation and subsidiaries
9.33%2026-04-22
INITIALThe Bank of New York Mellon Corporation (BNY) and each Group Entity listed in Annexure A (Group Entity)
5.00%2026-04-09
CEASED
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 competitor trialPhase 2+ · Non-ASX
Severe To Profound Sensorineural Hearing Loss1 active trial
1 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
15 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Pediatrics2026-04· Cochlear Implant
Otol Neurotol2026-04· Cochlear Implant
Ear Hear2026-04· Cochlear Implant
Acta Otolaryngol2026-04· Cochlear Implant
Catalysts (3)
Nucleus Nexa System global rollout
UpcomingExpectedremoveMed30 Sept 2026
TICI pivotal study primary completion (ENTERPRISE)
UpcomingConfirmedarrow_upwardHigh30 Apr 2027
TICI pivotal study full completion
UpcomingConfirmedarrow_upwardHigh31 Oct 2027
| Event | Type | Confidence | Impact | Date | Status |
|---|
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(47)
25 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1594d
Cochlear implant
Hear Again, Work Again
Hearing Loss, Sensorineural, Severe · Hearing Loss, Sensorineural, Bilateral · Hearing Loss, Unilateral +2 more
18 Years – 65 Years
Primary endpoint Change in sick leave after 3, 6 and 12 months
RecruitingOBSERVATIONALEnrollment stale · 352d
CI632DCI632
Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array
Sensorineural Hearing Loss · Bilateral Hearing Loss
18 Years+
Primary endpoint Comparison of Monopolar (MP1+2) Impedance Measurement (kOhms) between groups obtained in the CLTD5759 (NCT04750642) study, and at the 2 through 5 years post-activation routine follow-up visits.
NARecruitingEnrollment stale · 790d
Investigational Pre-Processing Algorithm (Sub A)Cochlear Limited standard-of-care pre-processing algorithmsInvestigational Pre-Processing Algorithm (Sub B)
New Algorithms to Signal Processing for Speech Enhancement in Adult Cochlear Implant Recipients.
Hearing Loss
RandomizedOpen Label18 Years+
Primary endpoint Australian Sentence Test in Noise (AuSTIN)